Outcome of transepithelial photorefractive keratectomy (PRK) for extreme myopia with Schwind Amaris SmartSurfACE laser beam profile

Session Details

Session Title: Surface Photoablation/PRK

Session Date/Time: Tuesday 25/09/2018 | 14:00-16:00

Paper Time: 15:10

Venue: Room A3, Podium 2

First Author: : S.Holland CANADA

Co Author(s): :    D. Lin   M. Al Obthani   S. Mosquera   C. Nithithanaphat           

Abstract Details

Purpose:

To evaluate 12-month post-operative outcomes of moderate and highly myopic eyes with transepithelial photorefractive keratectomy (TE-PRK) corrections using SCHWIND AMARIS (SA) 1050 with upgraded laser beam profile.

Setting:

Refractive Laser Clinic

Methods:

Retrospective case series. The outcomes of extreme myopic TE-PRK treatments performed with the SA1050 excimer laser with SmartSurfACE beam profile were evaluated at 12 months postoperatively. Refractive and visual comparisons of manifest refraction, uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), and safety (change of CDVA from baseline).

Results:

A total of 92 eyes with a mean pre-operative spherical equivalent refraction of -11.68±1.49D underwent SmartSurfACE PRK. The achieved treatment effect ranged from -10.1D to -16.9 D (mean -12.1D). 84 of 92 (91%) showed UDVA ≥20/40 post-operatively. 26 (28%) had improved CDVA, 4 (4%) had improved 2 lines or more while 4 (4%) lost 1 line. Post-operative UDVA and CDVA was well correlated with pre-operative CDVA with a statistically significant minimal improvement in both acuities. Only mild post-operative corneal haze noted, range 0 to 1.5 (average 0.3 +/- 0.4). Furthermore a statistically significant reduction in cylinder was also achieved.

Conclusions:

Trans-epithelial photorefractive keratectomy(TE-PRK) with Schwind Amauris SmartSurfACE excimer laser reported a sufficient safety and efficacy profile in eyes with extreme myopia (≥ -10 D) with 67% no change in CDVA. Nearly 30% of patients gained BCVA 1 lines or more postoperatively. TE-PRK procedure offers a good choice for correction of extreme myopia.

Financial Disclosure:

... is employed by a for-profit company with an interest in the subject of the presentation, ... travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, ... receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented